<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00430079</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02419</org_study_id>
    <secondary_id>UPCC# 1301</secondary_id>
    <secondary_id>R21CA093007</secondary_id>
    <secondary_id>CDR0000068962</secondary_id>
    <nct_id>NCT00430079</nct_id>
  </id_info>
  <brief_title>Use of EF5 to Measure the Oxygen Level in Tumor Cells of Patients Undergoing Surgery or Biopsy for Newly Diagnosed Supratentorial Malignant Glioma</brief_title>
  <official_title>Assessment of Hypoxia in Malignant Gliomas Using EF5</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This clinical trial is using EF5 to measure the oxygen level in tumor cells of patients&#xD;
      undergoing surgery or surgery biopsy for newly diagnosed supratentorial malignant glioma.&#xD;
      Diagnostic procedures using the drug EF5 to measure the oxygen level in tumor cells may help&#xD;
      in planning cancer treatment&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the presence and pattern of etanidazole derivative EF5 binding with tumor, based&#xD;
      on image and cellular analyses, in patients undergoing surgery or biopsy for newly diagnosed&#xD;
      supratentorial malignant gliomas.&#xD;
&#xD;
      II. Determine the level of EF5 binding within histologic subtypes of this tumor in these&#xD;
      patients.&#xD;
&#xD;
      Compare the relationship between hypoxia and clinical outcomes in patients with glioblastoma&#xD;
      multiforme (GBM) vs non-GBM.&#xD;
&#xD;
      III. Determine the spatial relationships between EF5 binding and tumor tissue biomarkers and&#xD;
      pathophysiologic processes (e.g., necrosis, proliferation, and apoptosis) in these patients.&#xD;
&#xD;
      IV. Determine the relationship between EF5 binding and Eppendorf needle electrode&#xD;
      measurements in these patients.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive etanidazole derivative EF5 IV over 1-2½ hours once within 1-2 days before&#xD;
      surgical resection or biopsy. Tumor tissue, normal tissue, and/or tumor-infiltrated lymph&#xD;
      node samples are collected during surgery and stained for biological markers. Fluorescent&#xD;
      immunohistochemistry techniques are used to determine the presence, distribution, and levels&#xD;
      of EF5 binding.&#xD;
&#xD;
      Patients are followed at 1 month, every 3 months for 1 year, every 4 months for 1 year, every&#xD;
      6 months for 1 year, and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 48 patients will be accrued for this study within 1½-2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Administratively complete.&#xD;
  </why_stopped>
  <start_date>July 2001</start_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to local recurrence</measure>
    <time_frame>Time from study entry (EF5 administration) to local recurrence, assessed up to 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to death</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence and pattern of EF5 binding in newly diagnosed brain masses by IHC analyses</measure>
    <time_frame>At 48 hours after EF5 administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of EF5 binding within histological subtypes of SMG</measure>
    <time_frame>At baseline, at 1 hour, and the time of surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between hypoxia and clinical outcomes (i.e., time to local recurrence and survival)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Time to local recurrence and survival will be estimated by the method of Kaplan and Meier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between EF5 binding and Eppendorf needle electrode measurements in brain masses</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The correlation between median oxygen pressure (pO2) by Eppendorf electrode measurement and percent of maximal signal in tumors (by EF5 binding) will be assessed by Pearson's correlation coefficient.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Adult Anaplastic Astrocytoma</condition>
  <condition>Adult Anaplastic Ependymoma</condition>
  <condition>Adult Anaplastic Oligodendroglioma</condition>
  <condition>Adult Diffuse Astrocytoma</condition>
  <condition>Adult Ependymoma</condition>
  <condition>Adult Giant Cell Glioblastoma</condition>
  <condition>Adult Glioblastoma</condition>
  <condition>Adult Gliosarcoma</condition>
  <condition>Adult Mixed Glioma</condition>
  <condition>Adult Myxopapillary Ependymoma</condition>
  <condition>Adult Oligodendroglioma</condition>
  <condition>Adult Pilocytic Astrocytoma</condition>
  <condition>Adult Pineal Gland Astrocytoma</condition>
  <condition>Adult Subependymoma</condition>
  <arm_group>
    <arm_group_label>Diagnostic (etanidazole)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive etanidazole derivative EF5 IV over 1-2½ hours once within 1-2 days before surgical resection or biopsy. Tumor tissue, normal tissue, and/or tumor-infiltrated lymph node samples are collected during surgery and stained for biological markers. Fluorescent immunohistochemistry techniques are used to determine the presence, distribution, and levels of EF5 binding.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etanidazole</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Diagnostic (etanidazole)</arm_group_label>
    <other_name>2-nitro-imidazole derivative</other_name>
    <other_name>SR-2508</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
    <description>Undergo surgery</description>
    <arm_group_label>Diagnostic (etanidazole)</arm_group_label>
    <other_name>surgery, conventional</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Diagnostic (etanidazole)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Diagnostic (etanidazole)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed and/or clinical and imaging evidence of a new brain mass that&#xD;
             is likely to be a supratentorial malignant glioma&#xD;
&#xD;
          -  Clinical condition and physiologic status indicative of debulking surgery or biopsy as&#xD;
             standard initial therapy&#xD;
&#xD;
          -  Performance status - Karnofsky performance status 60-100%&#xD;
&#xD;
          -  WBC greater than 2,000/mm^3&#xD;
&#xD;
          -  Platelet count greater than 90,000/mm^3&#xD;
&#xD;
          -  Creatinine less than 2.0 mg/dL&#xD;
&#xD;
          -  No significant cardiac condition that would preclude study therapy&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 1 month after study&#xD;
             completion&#xD;
&#xD;
          -  Weight no greater than 130 kilograms&#xD;
&#xD;
          -  No grade 3 or 4 peripheral neuropathy&#xD;
&#xD;
          -  No other invasive malignancy within the past 3 years that is likely to cause a&#xD;
             solitary supratentorial metastasis&#xD;
&#xD;
          -  No uncontrolled concurrent illness, medical condition, psychiatric illness, or social&#xD;
             situation that would preclude study participation&#xD;
&#xD;
          -  At least 6 months since prior chemotherapy&#xD;
&#xD;
          -  Concurrent corticosteroid therapy allowed&#xD;
&#xD;
          -  At least 6 months since prior radiotherapy to lesion or site of lesion&#xD;
&#xD;
          -  At least 6 months since prior surgery to lesion or site of lesion except incisional or&#xD;
             core biopsy&#xD;
&#xD;
          -  Concurrent anticonvulsant therapy allowed&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin Judy</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abramson Cancer Center of The University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>January 30, 2007</study_first_submitted>
  <study_first_submitted_qc>January 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2007</study_first_posted>
  <last_update_submitted>January 15, 2013</last_update_submitted>
  <last_update_submitted_qc>January 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Ependymoma</mesh_term>
    <mesh_term>Gliosarcoma</mesh_term>
    <mesh_term>Oligodendroglioma</mesh_term>
    <mesh_term>Glioma, Subependymal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanidazole</mesh_term>
    <mesh_term>Imidazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

